Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the ...

() -MeiraGTx Holdings has signed a deal with Eli Lilly, potentially worth over $475 million,​ granting the pharma giant ...

LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic ...

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children ...

MeiraGTx (MGTX) stock climbs as the company partners with Eli Lilly (LLY) to develop and sell gene therapies for eye diseases ...

Eli Lilly Strikes a Landmark Pricing Deal With the U.S. for Its Billion-Dollar Weight Loss Drugs. Here's What This Means for ...

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...

In the preceding three months, 12 analysts have released ratings for Eli Lilly (NYSE: LLY ), presenting a wide array of perspectives from bullish to bearish. The following table summarizes their ...

Eli Lilly will partner with Insilico Medicine on an artificial intelligence (AI)-based drug development collaboration that they said could generate “over $100 million” for the AI drug discovery ...

MeiraGTx Holdings shares rose sharply in premarket trading Monday after the clinical-stage genetic-medicines said it formed a ophthalmology collaboration potentially worth hundreds of millions of ...

Weight loss drugs are set to become a disproportionate share of Lilly's business.

Eli Lilly’s fair value estimate has recently been raised from $891.62 to $919.33. This reflects a modest increase in the company’s intrinsic valuation amid evolving market sentiment. The upward ...